Theranostic immunoliposomes for osteoarthritis

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 10, Issue 3, 2014, Pages 619-627

  Cho, Hongsik ^a,b,c   Stuart, John M ^c   Magid, Richard ^a   Danila, Delia C ^d   Hunsaker, Tamra ^d   Pinkhassik, Eugene ^d   Hasty, Karen A ^a,b,c  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b Campbell Clinnic   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF MEMPHIS   (United States)

Author keywords

Extracellular matrix (ECM); Immuno liposomes (ILs); Near infrared (NIR) fluorescent; Osteoarthritis (OA); Theranostic (therapeutic and diagnostic); Type II collagen (CII)

Indexed keywords

CARTILAGE; COLLAGEN; DISEASE CONTROL; DISEASES; DRUG DELIVERY; INFRARED DEVICES; JOINT PROSTHESES; JOINTS (ANATOMY); LIPOSOMES; ORGANIC POLYMERS;

EXTRACELLULAR MATRICES; IMMUNO-LIPOSOMES (ILS); NEAR INFRA RED; OSTEOARTHRITIS (OA); THERANOSTIC (THERAPEUTIC AND DIAGNOSTIC); TYPE II COLLAGENS;

DIAGNOSIS;

COLLAGEN ANTIBODY; COLLAGEN TYPE 2; IMMUNOLIPOSOME;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARTILAGE DEGENERATION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; INFANT; NONHUMAN; OSTEOARTHRITIS; PROPHYLAXIS;

ANIMALIA; CAVIA;

EXTRACELLULAR MATRIX (ECM); IMMUNO-LIPOSOMES (ILS); NEAR-INFRARED (NIR) FLUORESCENT; OSTEOARTHRITIS (OA); THERANOSTIC (THERAPEUTIC AND DIAGNOSTIC); TYPE II COLLAGEN (CII);

ANIMALS; CARTILAGE; COLLAGEN TYPE II; GUINEA PIGS; IMMUNOCONJUGATES; LIPOSOMES; OSTEOARTHRITIS;

EID: 84896547239     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2013.09.004     Document Type: Article

References (48)

1. Aspden R.M. Osteoarthritis: a problem of growth not decay?. Rheumatology 2008, 47:1452-1460.
2. Bitton R. The economic burden of Osteoarthritis. Am J Manag Care 2009, 15:230-235.
3. Wieland H.A., Michaelis M., Kirschbaum B.J., Rudolphi K.A. Osteoarthritis; an untreatable disease?. Nat Rev 2005, 4:331-344.
4. Elsaid K.A., Chichester C.O. Collagen markers in early arthritic diseases. Clin Chim Acta 2006, 365:68-77.
5. Jasin H.E., Noyori K., Takagi T., Taurog J.D. Characteristics of anti-type II collagen antibody binding to articular cartilage. Arthritis Rheum 1993, 36(5):651-659.
6. Quatman C.E., Hettrich C.M., Schmitt L.C., Spindler K.P. The Clinical Utility and Diagnostic Performance of Magnetic Resonance Imaging for Identification of Early and Advanced Knee Osteoarthritis: A Systematic Review. Am J Sports Med 2011, 39:1557-1568.
7. Leblond F., Davis S.C., Valdes P.A., Pogue B.W. Pre-clinical whole-body fluorescence imaging: Review of instruments, methods and applications. J Photochem Photobiol B 2010, 98(1):77-94.
8. Ameye L.G., Young M.F. Animal models of osteoarthritis: lessons learned while seeking the "Holy Grail". Curr Opin Rheumatol 2006, 18(5):537-547.
9. Bendele A.M. Animal models of osteoarthritis. J Musculoskelet Neuronal Interact 2001, 1(4):363-376.
10. Bendele A.M. Animal models of osteoarthritis in an era of molecular biology. J Musculoskelet Neuronal Interact 2002, 2(6):501-503.
11. Huebner J.L., Hanes M.A., Beekman B., Tekoppele J.M., Kraus V.B. A comparative analysis of bone and cartilage metabolism in two strains of guinea-pig with varying degrees of naturally occurring osteoarthritis. Osteoarthr Cartil 2002, 10:758-767.
12. Hollander A.P., Heathfield T.F., Webber C., Iwata Y., Boume R., Rorabeck C., et al. Increased damage to type II collagen in osteoarthritic articular cartilage detected by a new immunoassay. J Clin Invest 1994, 93:1722-1732.
13. Hovinga S., Seynhaevea A.L.B., Tiela S.T.V., Eggermonta A.M.M., Hagena T.L.M. Addition of low-dose tumor necrosis factor-a to systemic treatment with STEALTH liposomal doxorubicin (Doxil) improved anti-tumor activity in osteosarcoma-bearing rats. Anti-Cancer Drugs 2005, 16(6):667-674.
14. Noyori K., Koshino T., Takagi T., Okamoto R., Jasin H.E. Binding characteristics of antitype II collagen antibody to the surface of diseased human cartilage as a probe for tissue damage. J Rheumatol 1994, 21(2):293-296.
15. O'Connell J.P., Campbell R.L., Fleming B.M., Mercolino T.J., Jonhson M.D., McLaurin D.A. A highly sensitive immunoassay system involving antibody-coated tubes and liposome-entrapped dye. Clin Chem 1985, 31(9):1424-1426.
16. Scott R.C., Wang B., Nallamothu R., Pattillo C.B., Perez-Liz G., Issekutz A., et al. Targeted delivery of antibody conjugated liposomal drug carriers to rat myocardial infarction. Biotechnol Bioeng 2007, 96(4):795-802.
17. Ishida T., Iden D.L., Allen T.M. A combinatorial approach to producing sterically stabilized (stealth) Immunoliposomal drugs. FEBS Lett 1999, 460:129-133.
18. Leserman L.D., Machy P., Barbet J. Cell-specific drug transfer from liposomes bearing monoclonal antibodies. Nature 1981, 293(5829):226-228.
19. Maruyama K., Takizawa T., Takahashi N., Tagawa T., Nagaike K., Iwatsuru M. Targeting efficiency of PEG-Immunoliposome-conjugated antibodies at PEG terminals. Adv Drug Deliv Rev 1997, 24:235-242.
20. Lasic D., Papahadjopoulos D. Liposomes revisited. Science 1995, 267(5202):1275-1276.
21. Maruyama K. PEG-Immunoliposome. Biosci Rep 2002, 22(2):251-266.
22. Terato K., Hasty K.A., Reife R.A., Cremer M.A., Kang A.H., Stuart J.M. Induction of arthritis with monoclonal antibodies to collagen. J Immunol 1992, 148(7):2103-2108.
23. Achnyder A., Huwyler J. Drug transport to brain with targeted liposomes. J Am Soc Exp Neuro Ther 2005, 2:99-107.
24. Achnyder A., Krahenbuhl S., Torok M., Drewe J., Huwyler J. Targeting of skeletal muscle in vitro using biotinylated immunoliposomes. Biochem J 2004, 377:61-67.
25. Huwyler J., Yang J., Pardridge W.M. Receptor mediated delivery of daunomycin using immunoliposomes: pharmacokinetics and tissue distribution in the rat. J Pharmacol Exp Ther 1997, 282(3):1541-1546.
26. Huwyler J., Wu D., Pardridge W.M. Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci 1996, 93(24):14164-14169.
27. Olson F., Hunt C.A., Szoka F.C., Vali W.J., Papahadjopoulos D. Preparation of liposomes of defined size distribution by extrusion through polycarbonate membranes. Biochim Biophys Acta 1979, 557(1):9-23.
28. Rongen H.A.H., Bult A., van Benneekom W.P. Liposomes and immunoassays. J Immunol Methods 1997, 204:105-133.
29. Szoka F., Olson F., Heath T., Vail W., Mayhew E., Papahadjopoulos D. Preparation of unilamellar liposomes of intermediate size (0.1-0.2 um) by a combination of reverse phase evaporation and extrusion through polycarbonate membranes. Biochim Biophys Acta 1980, 601(3):559-571.
30. Harris E.D. Pathogenesis of Rheumatoid Arthritis. Textbook of Rheumatology 1985, 886-903. W. B. Saunders, Philadelphia. W. Kelley (Ed.).
31. Mankin H.J., Dorfman H., Lippiello L., Zarins A. Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips II. Correlation of morphology with biochemical and metabolic data. J Bone Joint Surg 1971, 53:523-537.
32. Moghimi S.M., Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog Lipid Res 2003, 42:463-478.
33. Torchilin V.P., Weissig V. Liposomes, Practical Approach. 2nd Edition 2003, Oxford University Press, Boston, MA.
34. Zhang L., Granick S. How to stabilize phospholipids liposomes. Nano Lett 2006, 6(4):694-698.
35. Liu D., Mori A., Huang L. Large liposomes containing ganglioside GM1 accumulate effectively in spleen. Biochem Biophys Acta 1991, 1066:159-165.
36. Liu D., Mori A., Huang L. Role of liposome size and RES blockade in controlling biodistribution and tumor uptake of GM-1 containing liposomes. Biochem Biophys Acta 1992, 1104:95-101.
37. Torchilin V.P. Recent advances with liposomes as pharmaceutical carriers. Nat Rev 2005, 4:145-160.
38. Torchilin V.P. Multifunctional and stimuli-sensitive pharmaceutical nanocarriers. Eur J Pharm Biopharm 2009, 71:431-444.
39. Vojta A., Scheuring J., Neumaier N., Mirus O., Weinkauf S., Schleiff E. Determination of liposome size: A tool for protein reconstitution. Anal Biochem 2005, 347:24-33.
40. Smith G.N. The role of collagenolytic matrix metalloproteinases in the loss of articular cartilage in osteoarthritis. Front Biosci 2006, 11:3081-3095.
41. Vanniasinghe A., Bender V., Manolios N. The potential of liposomal drug delivery for the treatment of inflammatory arthritis. J Semin Arthritis Rheum 2009, 39:182-196.
42. Tanaka H., Sugita T., Yasunaga Y., Shimose S., Deie M., Kubo T., et al. Efficiency of magnetic liposomal transforming growth factor-beta 1 in the repair of articular cartilage defects in a rabbit model. J Biomed Mater Res 2005, 73A:255-263.
43. Ballock R.T., Heydemann A., Wakefield L.M., Flanders K.C., Roberts A.B., Sporn M.B. Inhibition of the chondrocyte phenotype by retinoic acid involves upregulation of metalloprotease genes independent of TGF-beta. J Cell Physiol 1994, 159(2):340-346.
44. Pujol J.P., Galera P., Redini F., Mauviel A., Loyau G. Role of cytokines in osteoarthritis: comparative effects of interleukin 1 and transforming growth factor-beta on cultured rabbit articular chondrocytes. J Rheumatol Suppl 1991, 27:76-97.
45. Shlopov B.V., Gumanovskaya M.L., Hasty K.A. Autocrine regulation of collagenase 3 (matrix metalloproteinase 13) during osteoarthritis. Arthritis Rheum 2000, 43(1):195-205.
46. Shlopov B.V., Smith G.N., Cole A.A., Hasty K.A. Differential patterns of response to doxycycline and transforming growth factor beta1 in the down-regulation of collagenases in osteoarthritic and normal human chondrocytes. Arthritis Rheum 1999, 42(4):719-727.
47. Matrisian L.M. The matrix-degrading metalloproteinases. Bioessays 1992, 14(7):455-463.
48. Matrisian L.M., Ganser G.L., Kerr L.D., Pelton R.W., Wood L.D. Negative regulation of gene expression by TGF-beta. Mol Reprod Dev 1992, 32(2):111-120.